U.S. License Holder:
Altor BioScience, LLC
Date of License:
April-22-2024
Last Update:
Sep-30-2024
FDA-Approved Indications
ANKTIVA (nogapendekin alfa inbakicept-pmln) is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.